DURECT Corporation Presenting at the 4th Annual Smith Barney Citigroup Specialty Pharmaceuticals Conference

Download PDF:

CUPERTINO, Calif., Feb. 24 /PRNewswire-FirstCall/ — DURECT Corporation
(Nasdaq: DRRX) announced today that it will present at the Smith Barney
Citigroup Specialty Pharmaceuticals Conference. The conference is taking place
February 24-25th at The Marriott East Side Hotel in New York City, New York.
Dr. James E. Brown, President and Chief Executive Officer will be presenting
at the conference on Wednesday, February 25th at 8:00 a.m. Eastern Time.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO )

There will be a live webcast of the presentation from the Conference. The
webcast will be available on DURECT’s website under the Event Calendar section
of “Investor Relations.” The presentation will also be available for replay on
DURECT’s website for a period of up to 30 days after the conference.

About DURECT Corporation

DURECT Corporation (www.www.durect.com) is pioneering the development and
commercialization of pharmaceutical systems for the treatment of chronic
debilitating diseases and enabling biotechnology-based pharmaceutical
products. DURECT’s goal is to deliver the right drug to the right site in the
right amount at the right time. DURECT’s lead product in development is
CHRONOGESIC, a 3-month product for the treatment of chronic pain. DURECT also
owns three proprietary drug delivery platform technologies, including the
SABER Delivery System (a patented and versatile depot injectable useful for
protein and small molecule delivery), the MICRODUR(TM) Biodegradable
Microparticulates (microspheres injectable system) and the DURIN(TM)
Biodegradable Implant (drug-loaded implant system) upon which DURECT is
developing a pipeline of other products.

trademarks of DURECT Corporation.

The statements in this press release regarding DURECT’s products in
development and product development plans are forward-looking statements
involving risks and uncertainties that can cause actual results to differ
materially from those in such forward-looking statements. Potential risks and
uncertainties include, but are not limited to, DURECT’s ability to complete
the design, development, and manufacturing process development of its
products, manufacture and commercialize its products, obtain product and
manufacturing approvals from regulatory agencies, manage its growth and
expenses, manage relationships with third parties, finance its activities and
operations, as well as marketplace acceptance of DURECT’s products. Further
information regarding these and other risks is included in DURECT’s Annual
Report on Form 10-K for the fiscal year ended December 31, 2002 filed with the
SEC on March 14, 2003, DURECT’s Quarterly Report on Form 10-Q for the quarter
ended September 30, 2003 filed with the SEC on November 13, 2003 and other
periodic reports filed with the SEC under the heading “Factors that may affect
future results.”


CONTACT: Schond L. Greenway, Investor Relations and Strategic Planning
of DURECT Corporation, +1-408-777-1417/
/Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, +1-888-776-6555 or +1-212-782-2840/
/Web site: http://www.www.durect.com /

Scroll to Top